N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • ClinicalTrials.gov ID: NCT07867821

Registry updated: 2026-10-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Chronic arthropathy is one of the most common complications of haemophilia, affecting up to 90 per cent of patients aged 4 and over in at least one joint. the study aims to assess gene expression in biological samples collected via synovectomy and joint replacement surgery, as well as in peripheral blood, in patients with severe haemophilia A or B; to compare these data with those from patients with osteoarthritis and rheumatoid arthritis; and to correlate the gene expression data with information relating to the clinical and laboratory phenotype, the history of inhibitors, and ultrasound and histological findings.

Interventions

  • Surgery (Procedure)
    Participation in the study will be offered to patients with severe haemophilia A or B or to patients with osteoarthritis or rheumatoid arthritis and who, for clinical reasons, require a synovectomy or joint replacement surgery. Patients who give their consent for the collection of biological material will also have blood samples taken for the collection, storage and use of the samples within the timeframe specified by the study.

Eligibility criteria

Inclusion Criteria: * Diagnosis of severe haemophilia A or B * The need to perform therapeutic arthrocentesis, surgical synovectomy or orthopaedic joint replacement surgery for haemophilic arthropathy in all potentially affected joints. * signed informed consent Exclusion Criteria: * Current presence of an inhibitor (anti-FVIII or anti-FIX); * Inability to give informed consent to participate in the study.

Conditions

Hemophilia A and B

Locations

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record